Actos Lawsuit – Did you take Actos? Do you have bladder cancer?
Actos (Pioglitazone HCl) is the most widely prescribed medication for type II diabetes. Actos has been linked to an increased risk of bladder cancer. If you or someone you love has taken Actos and has been diagnosed with bladder cancer, you should find out your legal rights. Find out the facts behind the Actos Lawsuit. Contact our office by filling out the contact form or by giving us a call. The consultation is free. Our friendly staff and attorneys can answer your questions confidentially.
More than 10 million people have already taken Actos in an attempt to improve their glycemic or blood sugar control. A signifciant percentage of Actos users now, unfortunately, are dealing with a very serious side effect – bladder cancer.
Among these people, some are now filing Actos lawsuits to find out whether the manufacturer failed to properly warn of the very real risk. Did the manufacturer know? Did they properly warn?
Actos (Drug Information)
In July 15, 1999, Actos United States-Food Drug Administration (US-FDA) approval. The US-FDA approved Actos as an adjunct to diet and exercise in patients with type II diabetes mellitus. According to the patient medication guide for Actos, it is contra indicated in patients with type 1 diabetes mellitus and diabetic ketoacidosis. The active ingredient (Pioglitazone HCl) is available in the market in both single dosage form and in combination with other anti-diabetic ingredients.
Actos Side Effects (Heart Failure Risk)
On August 14, 2007, the US-FDA informed that all the Pioglitazone containing products (Actos, ACTOplus met, ACTOplus met XR, and duetact) of Takeda Pharmaceuticals might cause or exacerbate congestive heart failure. This information was based on FDA’s analysis of clinical trial data. The agency issued a black box warring for Actos and other Pioglitazone containing products. The US-FDA also recommended that the manufacturer add this information to the Warning, Precaution and Contraindication part of the label.
Actos Side Effects (Bladder Cancer Risk)
In clinical Studies, the use of Actos in patients with higher dosages for more than a year showed an increase in the risk of bladder cancer up to 40%.
The French government sponsored an epidemiological study and followed 155,000 Actos users over a three-year period between 2006 and 2009. This study found an increased risk of bladder cancer with long-term use of Actos. According to the result of this study, the healthcare regulators of France first recalled Actos from their market on June 9, 2011, and next, on June 10, 2011, the regulators in Germany recommended that physicians not prescribe Actos to new patients until further information about the cancer risk was released. Later, in June 2011, based on a planned ongoing ten year epidemiological study, which was conducted by the manufacturer of Actos, the US-FDA reviewed data from five-year interim analysis of that epidemiological study. That analysis seemed to confirm that the use of Actos for more than a year may increase the risk of bladder cancer in patients.
All is not yet known about the drug. What the manufacturer knew and when they knew it is important. Did the manufacturer place profit above the health of its own customers. The risk of cancer in rats was well known. Ongoing legal action on behalf of people who now suffer from bladder cancer after taking Actos will help lead to the truth.
Contact our office if you have bladder cancer and took Actos for a period of time. Learn your legal rights. The consultation is free an confidential.